ONCS - OncoSec Medical Incorporated

NasdaqCM - NasdaqCM Real Time Price. Currency in USD

OncoSec Medical Incorporated

24 North Main Street
Pennington, NJ 08534
United States

Full Time Employees37

Key Executives

NameTitlePayExercisedYear Born
Dr. Avtar S. DhillonChairman & Co-Founder170kN/A1962
Mr. Daniel J. O'Connor J.D.Pres, CEO & Director726.65kN/A1965
Mr. Punit S. Dhillon B.A., BACo-Founder & DirectorN/AN/A1980
Ms. Sara M. BonsteinCFO, COO & Company Sec.458.36kN/A1981
Dr. Christopher G. Twitty Ph.D.Chief Scientific OfficerN/AN/AN/A
Amounts are as of December 31, 2019 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


OncoSec Medical Incorporated, a biotechnology company, focuses on developing cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target and attack cancer. Its lead product candidate is ImmunoPulse IL-12 that uses electroporation device to deliver a DNA-encoded interleukin-12 for reversing the immunosuppressive microenvironment in the treated tumor. The company is also developing ImmunoPulse IL-12 with KEYTRUDA in patients with advanced melanoma that is in the Phase IIb clinical trials (KEYNOTE-695) and advanced or metastatic triple negative breast cancer (TNBC), which is in the Phase II clinical trials (KEYNOTE-890); ImmunoPulse IL-12 and KEYTRUDA in patients with advanced or metastatic melanoma that has completed Phase II clinical trials; and ImmunoPulse IL-12 monotherapy in patients with metastatic melanoma, which has completed the Phase II clinical trials. In addition, it undertakes the Phase II monotherapy biomarker study in patients with advanced or metastatic TNBC. Further, the company is developing new DNA-encoded therapeutic candidates and tumor indications. It has clinical trial collaborations with Merck & Co., Inc. and its subsidiary in connection with the KEYNOTE-695 and KEYNOTE-890 studies; a collaborative research agreement with Duke University School of Medicine to evaluate TAVOPLUS; a collaboration with Dana-Farber Cancer Institute and the Marasco Laboratory to develop CAR T-cell therapies for triple-negative breast cancer and ovarian cancer; and a research collaboration with Roswell Park Comprehensive Cancer Center to evaluate the use of Roswell Park's intravital microscopy and TAVO. The company was formerly known as NetVentory Solutions Inc. and changed its name to OncoSec Medical Incorporated in March 2011. The company was incorporated in 2008 and is headquartered in Pennington, New Jersey.

Corporate Governance

OncoSec Medical Incorporated’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.